In response to newly identified, community-based HIV epidemics, the National AETC Support Center has pulled together the following AETC Program and U...
Training slides review potential ARV drug-drug interactions and identify resources for the evaluation of drug-drug interactions.
Training slides define the HIV-ASSIST decision-support tool for ART selection and describe how it's used in different clinical scenarios.
Training slides provide an overview of the role of cabotegravir/rilpivirine injectables and other novel formulations in development for HIV treatment...
Case-based training slides review approaches and applications for second-line antiretroviral treatment regimens.
Immediate antiretroviral therapy (ART) means starting HIV treatment as soon as possible after the diagnosis of HIV infection, preferably on the first...
Training slides review the genotype versus phenotype resistance testing process; the indications for a traditional genotype, an integrase genotype, an...
(Recorded 5/10/23)
This training reviews ways to implement a comprehensive initial visit for a person with newly diagnosed HIV including engaging in mu...
Below is a list of the pocket guides created by the MidAtlantic AETC:
Training slides review how neutralizing antibodies (bNAbs) develop in people with HIV, identify the potential future uses of bNAbs to prevent, treat a...
Training slides review data on long-acting antiretrovirals (LA ART), challenges for its use, and LA ART future directions.
Training slides learning objectives include:
Training slides learning objectives include:
The National HIV Curriculum (NHC) provides free, up-to-date content for healthcare professionals to learn about HIV diagnosis, treatment, and preventi...
Training slides provide updates and a recent systematic review of the risk of HIV transmission with low viral loads.
Training slides provide an overview of Cabenuva including the latest study findings, adverse effects, resistance, and special dosing consi...
Browse recorded mini-lectures on clinically relevant topics including HIV Biology and Basic Science, Guideline Updates, Antiretroviral Medications, an...
Access recorded trainings presented by the AETC National Clinician Consultation Center (NCCC) in partnership with Health Resources and Serv...
This presentation lists strategies that reduce the risk of meningitis in people with HIV. Demonstrates how to recognize clinical symptoms...
This training slide presents updated data long acting injectable (LAI) cabotegravir/rilpivirine for treatment. Differentiate monitoring st...
This training presentation will compare factors that affect medication adherence and apply a patient centered approach to ART adherence.
Training slides cover the basic concepts of antiretroviral therapy (ART) virologic failure and resistance testing.
Training slides list reasons to consider switching antiretroviral (ARV) therapy in virologically suppressed patient according to HHS guidelines, revie...
Training slides review how to identify people who are appropriate for long-acting antiretroviral therapy (ART) for HIV treatment and prevention, appro...
These training slides review current literature on the efficacy of long-acting anti-retroviral therapy, reasons to switch from oral to long-acting ART...
The National HIV Curriculum just launched a new podcast exploring practice-changing issues and updates in HIV diagnosis, management, and prevention vi...
These guidelines provide information on updates on antiretroviral therapy (ART) for people with HIV who are trying to conceive.
This publication reviews the potential benefits and rationale for rapid antiretroviral therapy (ART) starts; outlines potential pitfalls; and offers p...
These slides provide information on new antiretroviral therapies and cardiovascular disease treatment options for people with HIV.
These slides provide basic information on Dolutegravir-Rilpivirine, an antiretroviral therapy (ART) treatment, including key drug interactions and stu...
These slides provide information on causes of creatinine elevation in people with HIV (PWH), workup of creatinine elevation, as well as the effects of...
This presentation provides current guidelines for the use of antiretroviral therapy (ART) agents in adults and adolescents with HIV.
This recorded webinar, summarizes the pharmacologic action and effectiveness, as well as the appropriateness of HIV treatment with cabotegravir/rilpiv...
The National Clinician Consultation Center Pharmacy contains the latest information on antiretroviral drugs and related resources, including NCCC-deve...
This new online self-paced course: Introduction to Long-Acting Antiretroviral Therapy- Cabotegravir/Rilpivirine (CAB/RPV), is the first in a new serie...
The popular AETC Program no-cost app supports health care providers with point-of-care tools for HIV screening, prevention, and care.
(Recorded on 4/3/25)
Updates from the 2025 Conference on Retroviruses and Opportunistic Infections. Presenters discuss the latest research and findings...
Find upcoming training programs, in-person events, online on-demand training, and an archive of recordings.
(Recorded on 1/12/2026)
Long-acting antiretrovirals are now becoming mainstream for the management of people with HIV who are virologically suppressed...
Selecting an antiretroviral (ARV) regimen requires careful consideration of multiple patient-specific factors, including virologic efficacy, resistanc...
The HIV Medication Chart is a two-page chart organized into the different categories of HIV antiretroviral medications...
Co-Author: Susa Coffey, MD; Medical Editor, AETC National Resource Center
An open-label study is evaluating the renal safety of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild, or the "quad" pill) and cobicistat. For those patients with mild-to-moderate renal impairment (estimated glomerula...
The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and deat...
There was a pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections in Boston in February. It evaluated concentrations of tenofovir (TFV) and TFV-diphosphate (DP) in genital and rectal tissue. Also in anogenital fluid samples after administration of oral tenofo...
Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg with b...
Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted darunavir du...
We know that very early treatment in acute HIV infection decreases HIV RNA; this study shows it also greatly decreases proviral DNA (and reservoir size). Researchers investigated 2 small cohorts of patients in Thailand with acute (and very early) HIV infection, 1 untreated and 1 treated with ART ver...
The EMERALD Study is a Phase III, open-label, noninferiority study in which 1,141 patients with stable HIV suppression on a regimen comprising a boosted protease inhibitor plus TDF/FTC were randomized (2:1) to either switch to an investigational single-tablet regimen containing darunavir 800 mg/cobi...
In July 2020, the U.S. Food and Drug Administration approved fostemsavir (FTR) for treatment of people with multi-drug resistant HIV-1 whose current ARV regimen is failing because of resistance, intolerance, or safety issues. FTR is a novel attachment inhibitor that binds the HIV envelope glycoprote...
The AETC Program's new resource combines the most up-to-date, HIV screening, prevention, and care resources in one mobile app, to provide access to essential point-of-care information and expert clinical support with just one touch.
HIV Care Tools is for busy clinicians from novice-to-expert, clinic...
Imagine: Ending HIV. It’s Possible. is the name of a new, national campaign that launched this summer to encourage and energize the HIV workforce to achieve the national goal of ending the HIV epidemic.
The U.S. Department of Health and Human Services introduced the Ending the HIV Epidemic in the U.S...
The FDA recently granted approval to lenacapavir (LEN), a novel long-acting HIV antiretroviral (ARV) that is classified as a capsid inhibitor. Lenacapavir is marketed in the United States as Sunlenca.
Lenacapavir blocks HIV-1’s assembly of its protein capsid and interferes with other steps in HIV rep...
